Skip to main content

Table 4 Odds ratios and 95% confidence intervals for association individual and concurrent metabolic comorbidities and risk of locoregional progression using binominal logistic regression, N = 1081. Individual and concurrent metabolic variables were included in the multivariable analysis

From: Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors

Presence of metabolic comorbidities With locoregional progression
N (%)
Without locoregional progression N (%) OR 95%CI P value
DM or glucose intolerance 149 (25.2%) 138 (28.2%) 0.853 0.650–1.118 0.249
Dyslipidemia 153 (25.8%) 146 (29.7%) 0.786 0.524–1.132 0.172
Hypertension 237 (41.9%) 225 (45.9%) 0.850 0.671–1.161 0.213
BMI risk 132 (22.3%) 120 (24.6%) 0.886 0.682–1.201 0.386
DM/glucose intolerance + Dyslipidemia 76 (12.8%) 71 (14.4%) 0.886 0.625–1.256 0.496
DM/glucose intolerance + Hypertension 123 (20.8%) 112 (22.8%) 0.860 0.643–1.151 0.311
Dyslipidemia + Hypertension 145 (24.5%) 134 (27.3%) 0.789 0.614–1.142 0.296
Dyslipidemia + BMI risk 62 (10.5%) 63 (12.8%) 0.771 0.621–1.201 0.252
Hypertension + BMI risk 86 (14.5%) 85 (17.3%) 0.803 0.661–1.193 0.241
DM/glucose intolerance + BMI risk 40 (6.8%) 42 (8.5%) 0.775 0.494–1.216 0.267
≥3 metabolic comorbidities 118 (20.0%) 110 (22.4%) 0.821 0.698–1.194 0.331
Any metabolic comorbidity 317 (53.6%) 289 (58.9%) 0.701 0.552–1.098 0.085